# A Phase Ⅱ Study of Anlotinib Combined With Tislelizumab and AT in the Neoadjuvant Treatment of Triple-negative Breast Cancer

> **NCT04914390** · PHASE2 · UNKNOWN · sponsor: **Sichuan Provincial People's Hospital** · enrollment: 32 (estimated)

## Conditions studied

- Triple-negative Breast Cancer

## Interventions

- **DRUG:** AT regimen
- **DRUG:** Tislelizumab
- **DRUG:** Anlotinib

## Key facts

- **NCT ID:** NCT04914390
- **Lead sponsor:** Sichuan Provincial People's Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-09-15
- **Primary completion:** 2025-03-31
- **Final completion:** 2025-09-30
- **Target enrollment:** 32 (ESTIMATED)
- **Last updated:** 2024-01-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04914390

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04914390, "A Phase Ⅱ Study of Anlotinib Combined With Tislelizumab and AT in the Neoadjuvant Treatment of Triple-negative Breast Cancer". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT04914390. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*